Takeru Shiroiwa

Summary

Publications

  1. ncbi request reprint The model-based cost-effectiveness analysis of 1-year adjuvant trastuzumab treatment: based on 2-year follow-up HERA trial data
    Takeru Shiroiwa
    Department of Drug Policy and Management, Graduate School of Pharmaceutical Sciences, The University of Tokyo, 7 3 1 Hongo, Bunkyo ku, Tokyo, 113 0033, Japan
    Breast Cancer Res Treat 109:559-66. 2008
  2. ncbi request reprint Cost-effectiveness analysis of bevacizumab combined with chemotherapy for the treatment of metastatic colorectal cancer in Japan
    Takeru Shiroiwa
    Department of Drug Policy and Management, Graduate School of Pharmaceutical Sciences, University of Tokyo, Tokyo, Japan
    Clin Ther 29:2256-67. 2007
  3. doi request reprint Cost-effectiveness analysis of KRAS testing and cetuximab as last-line therapy for colorectal cancer
    Takeru Shiroiwa
    Department of Drug Policy and Management, Graduate School of Pharmaceutical Sciences, University of Tokyo, Tokyo, Japan
    Mol Diagn Ther 14:375-84. 2010
  4. doi request reprint Comparison of Value Set Based on DCE and/or TTO Data: Scoring for EQ-5D-5L Health States in Japan
    Takeru Shiroiwa
    Department of Health and Welfare Services, National Institute of Public Health, Wako, Japan Electronic address
    Value Health 19:648-54. 2016
  5. pmc Long-term health status as measured by EQ-5D among patients with metastatic breast cancer: comparison of first-line oral S-1 and taxane therapies in the randomized phase III SELECT BC trial
    T Shiroiwa
    Department of Health and Welfare Services, National Institute of Public Health, 2 3 6 minami, Wako, Saitama, 351 0197, Japan
    Qual Life Res 26:445-453. 2017
  6. doi request reprint Societal Preferences for Interventions with the Same Efficiency: Assessment and Application to Decision Making
    Takeru Shiroiwa
    Department of Health and Welfare Service, National Institute of Public Health, 2 3 6 minami, Wako, Saitama, 351 0197, Japan
    Appl Health Econ Health Policy 14:375-85. 2016
  7. pmc Japanese population norms for preference-based measures: EQ-5D-3L, EQ-5D-5L, and SF-6D
    Takeru Shiroiwa
    Department of Health and Welfare Services, National Institute of Public Health, 2 3 6 minami, Wako, Saitama, 351 0197, Japan
    Qual Life Res 25:707-19. 2016
  8. doi request reprint QALY and productivity loss: empirical evidence for "double counting"
    Takeru Shiroiwa
    Center for Public Health Informatics, National Institute of Public Health, Saitama, Japan
    Value Health 16:581-7. 2013
  9. doi request reprint Cost-effectiveness of adjuvant FOLFOX therapy for stage III colon cancer in Japan based on the MOSAIC trial
    Takeru Shiroiwa
    Department of Biomedical Sciences, College of Life Sciences, Ritsumeikan University, Shiga, Japan
    Value Health 15:255-60. 2012
  10. doi request reprint Comparison of EQ-5D scores among anthracycline-containing regimens followed by taxane and taxane-only regimens for node-positive breast cancer patients after surgery: the N-SAS BC 02 trial
    Takeru Shiroiwa
    Department of Biomedical Sciences, College of Life Sciences, Ritsumeikan University, Shiga, Japan
    Value Health 14:746-51. 2011

Detail Information

Publications18

  1. ncbi request reprint The model-based cost-effectiveness analysis of 1-year adjuvant trastuzumab treatment: based on 2-year follow-up HERA trial data
    Takeru Shiroiwa
    Department of Drug Policy and Management, Graduate School of Pharmaceutical Sciences, The University of Tokyo, 7 3 1 Hongo, Bunkyo ku, Tokyo, 113 0033, Japan
    Breast Cancer Res Treat 109:559-66. 2008
    ..Therefore, we performed an economic analysis regarding the efficient distribution of medical resources...
  2. ncbi request reprint Cost-effectiveness analysis of bevacizumab combined with chemotherapy for the treatment of metastatic colorectal cancer in Japan
    Takeru Shiroiwa
    Department of Drug Policy and Management, Graduate School of Pharmaceutical Sciences, University of Tokyo, Tokyo, Japan
    Clin Ther 29:2256-67. 2007
    ..However, bevacizumab is an expensive medication, which costs from 300,000 yen to 400,000 yen (US $2500-$3300) per month...
  3. doi request reprint Cost-effectiveness analysis of KRAS testing and cetuximab as last-line therapy for colorectal cancer
    Takeru Shiroiwa
    Department of Drug Policy and Management, Graduate School of Pharmaceutical Sciences, University of Tokyo, Tokyo, Japan
    Mol Diagn Ther 14:375-84. 2010
    ..However, patients with a KRAS gene mutation do not benefit from cetuximab therapy...
  4. doi request reprint Comparison of Value Set Based on DCE and/or TTO Data: Scoring for EQ-5D-5L Health States in Japan
    Takeru Shiroiwa
    Department of Health and Welfare Services, National Institute of Public Health, Wako, Japan Electronic address
    Value Health 19:648-54. 2016
    ..Nevertheless, the characteristics of the statistical methods used for converting the EQ-5D-5L DCE results by using TTO information are not yet clearly known...
  5. pmc Long-term health status as measured by EQ-5D among patients with metastatic breast cancer: comparison of first-line oral S-1 and taxane therapies in the randomized phase III SELECT BC trial
    T Shiroiwa
    Department of Health and Welfare Services, National Institute of Public Health, 2 3 6 minami, Wako, Saitama, 351 0197, Japan
    Qual Life Res 26:445-453. 2017
    ..This study aimed to evaluate long-term health status of patients with MBC who participated in the phase III randomized SELECT BC trial...
  6. doi request reprint Societal Preferences for Interventions with the Same Efficiency: Assessment and Application to Decision Making
    Takeru Shiroiwa
    Department of Health and Welfare Service, National Institute of Public Health, 2 3 6 minami, Wako, Saitama, 351 0197, Japan
    Appl Health Econ Health Policy 14:375-85. 2016
    ..The second objective was to consider how this information regarding preferences could be used in decision making...
  7. pmc Japanese population norms for preference-based measures: EQ-5D-3L, EQ-5D-5L, and SF-6D
    Takeru Shiroiwa
    Department of Health and Welfare Services, National Institute of Public Health, 2 3 6 minami, Wako, Saitama, 351 0197, Japan
    Qual Life Res 25:707-19. 2016
    ..We also considered the relations between QOL score in the general population and socio-demographic factors...
  8. doi request reprint QALY and productivity loss: empirical evidence for "double counting"
    Takeru Shiroiwa
    Center for Public Health Informatics, National Institute of Public Health, Saitama, Japan
    Value Health 16:581-7. 2013
    ..When quality-adjusted life-years are used for economic evaluation, the controversial issue of "double counting" of productivity loss emerges, particularly given the lack of empirical data...
  9. doi request reprint Cost-effectiveness of adjuvant FOLFOX therapy for stage III colon cancer in Japan based on the MOSAIC trial
    Takeru Shiroiwa
    Department of Biomedical Sciences, College of Life Sciences, Ritsumeikan University, Shiga, Japan
    Value Health 15:255-60. 2012
    ..To evaluate the cost-effectiveness of adjuvant FOLFOX therapy versus 5-fluorouracil/leucovorin (FU/LV) for patients with stage III colorectal cancer...
  10. doi request reprint Comparison of EQ-5D scores among anthracycline-containing regimens followed by taxane and taxane-only regimens for node-positive breast cancer patients after surgery: the N-SAS BC 02 trial
    Takeru Shiroiwa
    Department of Biomedical Sciences, College of Life Sciences, Ritsumeikan University, Shiga, Japan
    Value Health 14:746-51. 2011
    ..We also investigated the relationship between Functional Assessment of Cancer Therapy (FACT) scale scores and EQ-5D utilities...
  11. pmc Cost-effectiveness analysis of trastuzumab to treat HER2-positive advanced gastric cancer based on the randomised ToGA trial
    T Shiroiwa
    Department of Biomedical Sciences, College of Life Sciences, Ritsumeikan University, Kusatsu, Shiga 525 8577, Japan
    Br J Cancer 105:1273-8. 2011
    ....
  12. doi request reprint Out-of-pocket payment and cost-effectiveness of XELOX and XELOX plus bevacizumab therapy: from the perspective of metastatic colorectal cancer patients in Japan
    Takeru Shiroiwa
    Department of Drug Policy and Management, Graduate School of Pharmaceutical Sciences, The University of Tokyo, Yakugaku toshokan 4F, 7 3 1 Hongo, Bunkyo ku, Tokyo, 113 0033, Japan
    Int J Clin Oncol 15:256-62. 2010
    ..The purpose of our study was to estimate the out-of-pocket payment and cost-effectiveness of capecitabine plus oxaliplatin (XELOX) or XELOX plus bevacizumab from the perspective of patients with metastatic colorectal cancer (MCRC)...
  13. doi request reprint Cost-effectiveness analysis of capecitabine compared with bolus 5-fluorouracil/l-leucovorin for the adjuvant treatment of colon cancer in Japan
    Takeru Shiroiwa
    Department of Drug Policy and Management, Graduate School of Pharmaceutical Sciences, The University of Tokyo, Tokyo, Japan
    Pharmacoeconomics 27:597-608. 2009
    ..A cost-effectiveness analysis of oral capecitabine versus intravenous bolus 5-fluorouracil/l-leucovorin (FU/LV) as adjuvant therapy in patients with stage 3 colon cancer was performed from a Japanese healthcare payer perspective...
  14. doi request reprint Health utility scores of colorectal cancer based on societal preference in Japan
    Takeru Shiroiwa
    Department of Drug Policy and Management, Graduate School of Pharmaceutical Sciences, The University of Tokyo, Tokyo, Japan
    Qual Life Res 18:1095-103. 2009
    ..We measured health utility scores of colorectal cancer (CRC) patients from a societal perspective in Japan...
  15. pmc Cost-effectiveness analysis of XELOX for metastatic colorectal cancer based on the NO16966 and NO16967 trials
    T Shiroiwa
    Department of Drug Policy and Management, Graduate School of Pharmaceutical Sciences, The University of Tokyo, Tokyo, Japan
    Br J Cancer 101:12-8. 2009
    ....
  16. doi request reprint International survey on willingness-to-pay (WTP) for one additional QALY gained: what is the threshold of cost effectiveness?
    Takeru Shiroiwa
    Department of Drug Policy and Management, Graduate School of Pharmaceutical Sciences, The University of Tokyo, 7 3 1, Hongo, Bunkyo ku, Tokyo, Japan
    Health Econ 19:422-37. 2010
    ..8% (Japan), 3.7% (ROK), 1.6% (Taiwan), 2.8% (UK), 1.9% (Australia), and 3.2% (US). Based on the current study, we suggest new classification of cost-effectiveness plane and methodology for decision making...
  17. ncbi request reprint [Pharmacoeconomics of molecular target drugs in Japan]
    Kiichiro Tsutani
    Department of Drug Policy and Management, Graduate Schools of Pharmaceutical Sciences, The University of Tokyo
    Nihon Rinsho 68:1923-8. 2010
    ..With this data, we are taking various pharmacoeconomic analysis...